Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/KATP channel pathway and PPARγ receptors

2020 ◽  
pp. 1-8
Author(s):  
Ehsan Alizamani ◽  
Behnam Ghorbanzadeh ◽  
Reza Naserzadeh ◽  
Mohammad Taghi Mansouri
Keyword(s):  
Nitric Oxide ◽  
Animal Model ◽  
Receptor Antagonist ◽  
Cyclic Gmp ◽  
Katp Channel ◽  
Leukotriene Receptor Antagonist ◽  
Cysteinyl Leukotriene ◽  
Leukotriene Receptor ◽  
Cysteinyl Leukotriene Receptor

scholarly journals Ecchymosis: An Unexpected Side Effect of Montelukast

2020 ◽  
Vol 18 (3) ◽  
pp. 156-158
Author(s):  
Gokce Eser ◽  
Mustafa Berber ◽  
Hulya Ercan Sarıcoban
Keyword(s):  
Receptor Antagonist ◽  
Side Effect ◽  
Drug Reactions ◽  
Leukotriene Receptor Antagonist ◽  
Cysteinyl Leukotriene ◽  
Rare Side Effect ◽  
Leukotriene Receptor ◽  
Cysteinyl Leukotriene Receptor ◽  
Allergy And Asthma

Montelukast is a leukotriene receptor antagonist that is used to treat allergy and asthma. It acts as a cysteinyl leukotriene receptor antagonist that blocks the action of leukotrienes and decreases inflammation. This agent is generally well tolerated in clinical practice. Although montelukast is generally considered as a safe drug, it can cause a few adverse drug reactions. In this case study, a rare side effect of montelukast that has been reported only twice before is presented. The importance of this case report is that the youngest patient who had ecchymosis due to the use of montelukast treatment is reported

Sign in / Sign up

Export Citation Format

Share Document